142 related articles for article (PubMed ID: 28043125)
1. Inhibition of Breast Cancer Resistance Protein and Multidrug Resistance Associated Protein 2 by Natural Compounds and Their Derivatives.
Sjöstedt N; Holvikari K; Tammela P; Kidron H
Mol Pharm; 2017 Jan; 14(1):135-146. PubMed ID: 28043125
[TBL] [Abstract][Full Text] [Related]
2. Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Pedersen JM; Matsson P; Bergström CA; Norinder U; Hoogstraate J; Artursson P
J Med Chem; 2008 Jun; 51(11):3275-87. PubMed ID: 18457386
[TBL] [Abstract][Full Text] [Related]
3. A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP.
Xiao L; Yi T; Chen M; Lam CW; Zhou H
Eur J Pharm Sci; 2016 Oct; 93():456-67. PubMed ID: 27586020
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of terpenoids on multidrug resistance-associated protein 2- and breast cancer resistance protein-mediated transport.
Yoshida N; Takada T; Yamamura Y; Adachi I; Suzuki H; Kawakami J
Drug Metab Dispos; 2008 Jul; 36(7):1206-11. PubMed ID: 18436619
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
Breedveld P; Zelcer N; Pluim D; Sönmezer O; Tibben MM; Beijnen JH; Schinkel AH; van Tellingen O; Borst P; Schellens JH
Cancer Res; 2004 Aug; 64(16):5804-11. PubMed ID: 15313923
[TBL] [Abstract][Full Text] [Related]
6. Substrate and method dependent inhibition of three ABC-transporters (MDR1, BCRP, and MRP2).
Pedersen JM; Khan EK; Bergström CAS; Palm J; Hoogstraate J; Artursson P
Eur J Pharm Sci; 2017 May; 103():70-76. PubMed ID: 28263911
[TBL] [Abstract][Full Text] [Related]
7. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.
Katayama K; Masuyama K; Yoshioka S; Hasegawa H; Mitsuhashi J; Sugimoto Y
Cancer Chemother Pharmacol; 2007 Nov; 60(6):789-97. PubMed ID: 17345086
[TBL] [Abstract][Full Text] [Related]
8. Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone.
Lagas JS; van der Kruijssen CM; van de Wetering K; Beijnen JH; Schinkel AH
Drug Metab Dispos; 2009 Jan; 37(1):129-36. PubMed ID: 18845662
[TBL] [Abstract][Full Text] [Related]
9. Glyceollin Effects on MRP2 and BCRP in Caco-2 Cells, and Implications for Metabolic and Transport Interactions.
Chimezie C; Ewing A; Schexnayder C; Bratton M; Glotser E; Skripnikova E; Sá P; Boué S; Stratford RE
J Pharm Sci; 2016 Feb; 105(2):972-981. PubMed ID: 26296158
[TBL] [Abstract][Full Text] [Related]
10. Interaction of Food Additives with Intestinal Efflux Transporters.
Sjöstedt N; Deng F; Rauvala O; Tepponen T; Kidron H
Mol Pharm; 2017 Nov; 14(11):3824-3833. PubMed ID: 28921988
[TBL] [Abstract][Full Text] [Related]
11. Binding Site Interactions of Modulators of Breast Cancer Resistance Protein, Multidrug Resistance-Associated Protein 2, and P-Glycoprotein Activity.
Deng F; Ghemtio L; Grazhdankin E; Wipf P; Xhaard H; Kidron H
Mol Pharm; 2020 Jul; 17(7):2398-2410. PubMed ID: 32496785
[TBL] [Abstract][Full Text] [Related]
12. Zinc finger nuclease-mediated gene knockout results in loss of transport activity for P-glycoprotein, BCRP, and MRP2 in Caco-2 cells.
Sampson KE; Brinker A; Pratt J; Venkatraman N; Xiao Y; Blasberg J; Steiner T; Bourner M; Thompson DC
Drug Metab Dispos; 2015 Feb; 43(2):199-207. PubMed ID: 25388687
[TBL] [Abstract][Full Text] [Related]
13. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
Dahan A; Amidon GL
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
Pick A; Müller H; Mayer R; Haenisch B; Pajeva IK; Weigt M; Bönisch H; Müller CE; Wiese M
Bioorg Med Chem; 2011 Mar; 19(6):2090-102. PubMed ID: 21354800
[TBL] [Abstract][Full Text] [Related]
15. Hop-derived prenylflavonoids are substrates and inhibitors of the efflux transporter breast cancer resistance protein (BCRP/ABCG2).
Tan KW; Cooney J; Jensen D; Li Y; Paxton JW; Birch NP; Scheepens A
Mol Nutr Food Res; 2014 Nov; 58(11):2099-110. PubMed ID: 25044854
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel dietary phytochemicals inhibiting the efflux transporter breast cancer resistance protein (BCRP/ABCG2).
Tan KW; Li Y; Paxton JW; Birch NP; Scheepens A
Food Chem; 2013 Jun; 138(4):2267-74. PubMed ID: 23497885
[TBL] [Abstract][Full Text] [Related]
17. Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein.
Zhang S; Yang X; Coburn RA; Morris ME
Biochem Pharmacol; 2005 Aug; 70(4):627-39. PubMed ID: 15979586
[TBL] [Abstract][Full Text] [Related]
18. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
Köhler SC; Wiese M
J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
[TBL] [Abstract][Full Text] [Related]
19. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense.
Leslie EM; Deeley RG; Cole SP
Toxicol Appl Pharmacol; 2005 May; 204(3):216-37. PubMed ID: 15845415
[TBL] [Abstract][Full Text] [Related]
20. Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2).
Merino G; Jonker JW; Wagenaar E; Pulido MM; Molina AJ; Alvarez AI; Schinkel AH
Drug Metab Dispos; 2005 May; 33(5):614-8. PubMed ID: 15703302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
